BioCentury | Nov 21, 2019
Financial News

Nov. 20 Financial Quick Takes: Diagnostics play Lucence raises series A; plus Novo-Broad, PMV, Phoenix, Winterlight and BMS-Celgene

A*STAR spinout Lucence raises $20M IHH led a $20 million series A round for Lucence, a blood-based cancer diagnostics company spun out of Singapore’s Agency for Science, Technology and Research (A*STAR) in 2016. The company...
BioCentury | Feb 22, 2019
Targets & Mechanisms

Expansion into TNBC

With an RNA-binding small molecule that sensitizes HER2-negative cancers to Herceptin, Matt Disney’s latest study adds to the growing arsenal of preclinical therapies against triple-negative breast cancer. The only problem is the molecule may run...
BioCentury | Feb 9, 2019
Company News

Emerging company roundup: HiberCell, Orexia, TamRx

At least five new biotechs launched this week to develop therapies spanning rare sleep disorders to cancer immunotherapy, while several other emerging companies are moving closer to key inflection points. Of the five newcos, HiberCell...
BioCentury | Feb 8, 2019
Product R&D

Reducing R(i)SK in TNBC

Phoenix Molecular Designs could provide triple-negative breast cancer its first molecular marker to turn the intractable indication from a group of have-nots to a group of haves. With early evidence that RSK2 is activated in...
BioCentury | Jan 18, 2019
Company News

Phoenix, Roche partner to develop TNBC biomarker

Phoenix Molecular Designs (Vancouver, B.C.) and Roche (SIX:ROG; OTCQX:RHHBY) partnered on Jan. 16 to develop a molecular diagnostic to help stratify triple-negative breast cancer patients. Roche will develop an assay to detect activation of RPS6KA3,...
BioCentury | Jan 17, 2019
Company News

Phoenix, Roche partner to develop TNBC biomarker

Phoenix Molecular Designs (Vancouver, B.C.) and Roche (SIX:ROG; OTCQX:RHHBY) partnered on Wednesday to develop a molecular diagnostic to help stratify triple-negative breast cancer patients. Roche will develop an assay to detect activation of RPS6KA3, which...
BioCentury | Jan 31, 2018
Distillery Techniques

Biomarkers

TECHNOLOGY: Tissue markers Tumor levels of RPS6KA5 could help predict survival in ESR1-positive breast cancer. In 193 patients, low primary tumor levels of RPS6KA5 mRNA were associated with poor metastasis-free survival. In another 214 patients,...
BioCentury | Sep 5, 2013
Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers Ribosomal protein S6 kinase (RSK) phosphorylation to predict response to BRAF, MEK or phosphoinositide 3-kinase (PI3K) inhibitors Studies in patient samples, cell culture and mice suggest...
BioCentury | Jun 27, 2013
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Ataxia Ribosomal protein S6 kinase 90 kDa polypeptide 5 (RPS6KA5; MSK1); ataxin 1 (ATXN1) Fly and mouse studies suggest inhibiting MSK1...
BioCentury | May 23, 2013
Distillery Therapeutics

Indication: Cancer

...RSK3); RPS6KA6 (RSK4); phosphoinositide-3 kinase (PI3K) Cell culture and mouse studies suggest inhibiting RSK3 and RSK4...
...cancers resistant to PI3K inhibitors. In cultured breast cancer cells, vector-mediated overexpression of RSK3 or RSK4...
...control vector. In mouse xenograft models for human breast cancer, vector-mediated overexpression of RSK3 or RSK4...
Items per page:
1 - 10 of 16